Surgalign Holdings (OTCPK:SRGA.Q) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

SRGA.Q Aperçu des actions

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide.

A propos de l'entreprise

SRGA.Q analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	0/6
Dividendes	0/6

Récompenses

Analyse des risques

Les revenus ont diminué de 9.6% par an au cours des 5 dernières années

N'a pas de capitalisation boursière significative ( $165K )

Capitaux propres négatifs

Cours de l'action très volatil au cours des 3 derniers mois

+ 2 plus de risques

Surgalign Holdings, Inc. Concurrents

InVitro International

OTCPK:IVRO

US$1.2m

Procyon

OTCPK:PCYN

US$1.9m

Vycor Medical

OTCPK:VYCO

US$1.9m

Wearable Health Solutions

OTCPK:WHSI

US$182.7k

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Surgalign Holdings
Historique des cours de bourse
Prix actuel de l'action	US$0.018
Plus haut sur 52 semaines	US$4.00
Plus bas sur 52 semaines	US$0.005
Bêta	1.49
1Variation sur 1 mois	63.64%
Variation sur 3 mois	-80.00%
Variation sur 1 an	-99.50%
3Variation sur 3 ans	-99.97%
Variation sur 5 ans	-99.99%
Évolution depuis l'introduction en bourse	-100.00%

Nouvelles et mises à jour récentes

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Rendement pour les actionnaires

	SRGA.Q	US Medical Equipment	US Marché
7D	16.1%	1.2%	0.07%
1Y	-99.5%	12.1%	22.7%

Rendement vs Industrie: SRGA.Q a sous-performé le secteur US Medical Equipment qui a rapporté 11.2 % au cours de l'année écoulée.

Rendement vs marché: SRGA.Q a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	8.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de SRGA.Q a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de SRGA.Q est passée de 28% à 40% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Surgalign Holdings se comparent-ils à sa capitalisation boursière ?
SRGA.Q statistiques fondamentales
Capitalisation boursière	US$165.30k
Bénéfices(TTM)	-US$50.49m
Recettes(TTM)	US$78.12m

0.0x

Ratio P/S

0.0x

Ratio P/E

Le site SRGA.Q est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
SRGA.Q compte de résultat (TTM)
Recettes	US$78.12m
Coût des recettes	US$26.03m
Marge brute	US$52.09m
Autres dépenses	US$102.58m
Les revenus	-US$50.49m

Derniers bénéfices déclarés

Mar 31, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-5.50
Marge brute	66.68%
Marge bénéficiaire nette	-64.63%
Ratio dettes/capitaux propres	-54.1%

Quelles ont été les performances à long terme de SRGA.Q?

Voir les performances historiques et les comparaisons

SRGA.Q Aperçu des actions

Récompenses

Analyse des risques

Surgalign Holdings, Inc. Concurrents

OTCPK:IVRO

US$1.2m

OTCPK:PCYN

US$1.9m

OTCPK:VYCO

US$1.9m

OTCPK:WHSI

US$182.7k

Historique des prix et performances

Nouvelles et mises à jour récentes

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)